drugset / Trial / NCT05396118
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
NaSingle-groupOpen-labelDiagnostic
Summary
Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized \[1-13C\]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner in patients with cancer.
Timeline
- Start
- 2022-05-18
- Primary completion
- 2024-08
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 4 mbq/kg | — |
| Subject | [1-13C]Pyruvate | Diagnostic / imaging agent | 0.43 unknown | — |